Description

POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research[1][2].—Metabolism-protein/nucleotide metabolism–C74H103F3N22O20S2—-[1]S. Kaushal, et al. Complement C3 inhibitor POT-4: Clinical Safety of Intravitreal Administration. ARVO Annual Meeting Abstract, 2009 Apr.|[2]Robyn Troutbeck, et al. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. Jan-Feb 2012;40(1):18-26.—-1741.87—-CN1C2=CC=CC=C2C(C[C@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N3)=O)C(C)C)=O)NC([C@@H](NC(C)=O)[C@@H](C)CC)=O)C(N[C@H](C(N)=O)[C@H](O)C)=O)=O)CCCNC(N)=N)=O)CC4=CN=CN4)=O)C)=O)=O)CC5=CNC6=CC=CC=C56)=O)CC(O)=O)=O)CCC(N)=O)=O)=C1.O=C(O)C(F)(F)F–Metabolic Disease–10 mM in DMSO–Complement System—-Immunology/Inflammation–Peptides